Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
about
Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligandsAnalogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinityMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationUnderstanding functional residues of the cannabinoid CB1.Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated ratsEnhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient miceAnandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bedhCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.Functional role of cannabinoid receptors in urinary bladder.Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor.Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivativesThe effects of targeted deletion of cannabinoid receptors CB1 and CB2 on intranasal sensitization and challenge with adjuvant-free ovalbuminEndocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.Cannabinoid receptors and their relationships with neuropsychiatric disorders.Probing the interaction of SR141716A with the CB1 receptor.Cannabinoid receptors and the regulation of bone mass.Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinolImmunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.Cannabinoids and the skeleton: from marijuana to reversal of bone loss.CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases.Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells.Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activitiesThe importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system.Reciprocal inhibition of voltage-gated potassium currents (I K(V)) by activation of cannabinoid CB1 and dopamine D1 receptors in ON bipolar cells of goldfish retina.Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis.
P2860
Q24643941-82DDA591-1F38-43EE-A450-5147A706F7FEQ24650317-67A02FD5-DF9D-47F9-B1CB-7AC5BFA0151AQ26829111-91B4AF8D-61DA-4620-94EA-16D022F231AAQ27687653-FB3EE8A2-DD65-47E9-BC1A-F75C7E17E68CQ28271665-2ABBE17A-D1EC-4CD7-92EC-05FE4B410159Q28360131-B61899A9-B4A4-4FA0-8728-B7CB7BD5DFE1Q28579681-41FA9DE5-3E10-48BD-B82C-FC92BB479FEEQ33733994-AB691BD1-4683-4EA6-BE4A-7BD5F25897BCQ33884859-752BDF12-5406-4E2A-951D-0BD0C4CE3625Q33925431-E6DF70B0-BE4C-4A9D-A668-D7D291DEBA27Q33997873-E3BBD557-F8D2-4F57-8A06-7B221616844CQ34004234-5C1F5AF3-AE84-47B7-A5AA-0DDDEBD0AC96Q34136743-4A5CCE90-0525-48DE-9978-472DC5505601Q34331157-8B14084E-2FBF-42FD-8E98-F22583AA3FA5Q36033414-209C4E9F-AC0E-45D9-BAF1-2368F09BD9FCQ36385826-0B5D70C5-A81C-4061-AF52-1FEA94B230BEQ36416382-603C55A8-7E37-48DA-BAFC-B46788EDA91FQ37039010-AC96AF6D-F8DC-482F-B770-67D49C466C81Q37244823-49A4A0C5-0FDE-4D78-971E-AD28FE54E824Q37563061-7136775C-108D-469C-80D2-CA26D424D14DQ37899264-97470AB5-7EC8-4710-A37E-0E3D87754B12Q38072055-6D25D405-AB1B-4493-BB9F-3E2E1DDD8DD3Q40612911-C8BE430F-F501-494D-971E-4CAF7193B6B0Q41895092-C45CACA0-83F8-401E-80A7-D6DF1BD534B6Q42940086-76E1AE7A-80F9-485F-8120-2CBF776E8CF7Q45216079-34EC405A-BBF4-45F1-B41A-5DE7C6ABA078Q46447396-F656E32B-043E-48A9-923C-D3BB24DCE4A1Q50949437-5C2157EA-F143-4FEA-B25E-05F589E596B3
P2860
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@ast
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@en
type
label
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@ast
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@en
prefLabel
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@ast
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@en
P2093
P921
P1433
P1476
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
@en
P2093
B Calandra
M Bouaboula
M Rinaldi-Carmona
P Casellas
P304
P356
10.1016/S0024-3205(99)00285-4
P407
P577
1999-01-01T00:00:00Z